Ryvu Therapeutics in 2026: a Kraków oncology biotech, RVU120 in Phase II clinical trials, a six-member management board, an mWIG40 issuer after the Selvita spin-off

Ryvu Therapeutics in 2026: a Kraków oncology biotech, RVU120 in Phase II clinical trials, an mWIG40 issuer after the Selvita spin-off

Ryvu Therapeutics S.A. - headquartered at ul. Leona Henryka Sternbacha 2 in Kraków (postcode 30-394), registered in the KRS under number 0000367359 - is a Polish oncology biotech developing small-molecule drugs targeting cancer. The company was created in its current corporate form on 6 October 2010, but in its current business structure as a separated biotech it has operated since 2019 - after the Selvita spin-off, which retained the contract R&D services segment for the pharmaceutical industry.

This is a rare case of a Polish corporate spin-off with a stock-market component: two stock-listed companies (Selvita - R&D services, Ryvu - own biotech pipeline) emerge from a single hub and share historic know-how. Ryvu is the higher-risk part - pre-commercial, approaching a breakthrough in its own clinical projects. Selvita (listed separately) is lower-risk - a contract CRO with stable revenue from pharmaceutical clients.

RYVU Therapeutics

KRAKÓW · KRS 0000367359 · SPÓŁKA AKCYJNA

Revenue

42.6 M PLN

Sternbacha 2, Kraków: Kraków SSE as the heart of Polish biotech

The address ul. Leona Henryka Sternbacha 2, 30-394 Kraków, places Ryvu's seat in the Kraków Special Economic Zone - in the biotechnology cluster which, alongside Comarch (IT) and Grupa Azoty (chemicals), forms the modern-industries base in the Małopolskie voivodeship. The SSE location offered tax incentives in the 2010s for new innovation-investing companies - which enabled Ryvu / Selvita to expand R&D laboratories.

The company has a registered electronic-delivery address (ADE: PL-89571-20056-VTTUV-14) and a website at ryvu.com (.com reflects the global pharmaceutical-customer reach - Ryvu conducts clinical trials in the US and EU). Governance: a six-member management board (CEO plus five management-board members) and a seven-member supervisory board.

Under Polish PKD codes the principal activity codes include 72 (scientific research and development) - including 7211 (research in biotechnology) - and 21 (manufacture of basic pharmaceutical products). The same set of codes applies to Mabion and other Polish public biotech issuers.

Polish biotech-oncology sector: Ryvu as the only pure pre-commercial mWIG40 player

In the Polish stock-listed biotech-oncology sector Ryvu Therapeutics occupies a unique position as the only large, pure pre-commercial player in the mWIG40:

• Mabion (Konstantynów Łódzki) - biotech with a Novavax CDMO contract (post-revenue), plus an own biosimilars pipeline. Risk cushioned by the contract revenue stream.
• Selvita - contract CRO (commissioned research), no own projects. Stable operating business but no upside from an own pipeline.
• Ryvu Therapeutics - pure pre-commercial biotech: no significant revenue beyond grants and partnerships. Valuation entirely depends on RVU120 progress and the next clinical projects.

Three structural features of the Ryvu model that explain its mWIG40 positioning:

• Pipeline as the only asset - unlike Mabion (contract + pipeline) or Selvita (CRO contract), Ryvu's valuation entirely depends on the potential of its own clinical projects. RVU120 (a CDK8/19 inhibitor) is the flagship project - being developed in Phase II in multiple oncological indications (AML, MDS, glioblastoma, sarcomas). Positive results = multifold price increases; failures = sharp falls.
• International partnerships as a financial stabiliser - Ryvu has signed partnerships with US-based Exelixis and Italy's Menarini on selected pipeline projects. Every upfront payment + milestone payment from partnerships is a meaningful revenue stream during the pre-commercial period. The partnerships themselves are also a technology validation.
• Sector specifics - binary valuation - biotech companies on the exchange often record extreme moves. Ryvu, as a pre-commercial player, inherits this characteristic to the greatest degree - more than Mabion or Selvita. A minority investor must accept high risk tolerance.

Implication for the investment profile: pre-commercial biotech, zero dividend, key is RVU120

“Ryvu Therapeutics is the Polish case of a pure pre-commercial biotech - a company whose stock-market value depends almost entirely on the progress of its own clinical projects. RVU120 is the flagship project - the first own-pipeline drug at advanced clinical stage. Positive Phase II results = multifold price rises; failure = sharp drop. This is a venture-capital-like investment on a classical exchange, for investors accepting high valuation volatility.”

Three expected consequences for the company's 2026 investment profile:

• Zero dividend policy - Ryvu has never paid a dividend and probably will not before the commercialisation of RVU120 or another project. All cash flow (from grants, partnerships) returns to R&D. A minority investor earns purely on price appreciation.
• Key: RVU120 progress in 2026 - in 2026 further Phase II results for RVU120 in key oncological indications are expected. Positive results translate into multifold valuation rises; failures have for biotech tickers ranged from -50% to -70%. This makes Ryvu the highest-risk ticker in the Polish mWIG40.
• International partnerships as a buffer - in a year when RVU120 results are volatile, the Exelixis/Menarini partnerships stabilise revenue from milestone payments. This makes the company less exposed to immediate cash-burn risk, although long-term commercialisation of own projects remains critical.

For Małopolska itself, Ryvu Therapeutics is the third mWIG40 issuer in the region (after Comarch and Grupa Azoty in Tarnów) - Kraków as the regional capital has strong stock-market representation in the tech sector (Comarch) and biotech (Ryvu). Together with Mabion (Konstantynów Łódzki), Ryvu represents the Polish biotech mWIG40 - a narrow but prestigious segment.

What you'll find in the Ryvu Therapeutics profile

The Ryvu Therapeutics S.A. profile in our database carries the full picture of the company: composition of the six-member management board (CEO plus five management-board members), the seven-member supervisory board, the KRS registration history from 6 October 2010 (with traces of the 2019 spin-off from Selvita), the registered address at ul. Leona Henryka Sternbacha 2 in Kraków SSE, e-delivery status (ADE PL-89571-20056-VTTUV-14), website ryvu.com, and the assigned PKD codes classifying the activity as biotechnology. The profile is also available in English - important for international biotech-fund investors, since Ryvu is the only Polish pure pre-commercial biotech mWIG40 issuer.

Data: Polish KRS Court Register (KRS 0000367359); Ryvu Therapeutics S.A. - annual reports 2023–2025; PKD classification 72/21 (biotechnology); company history - founded within Selvita, S.A. 2010, spin-off and independent WSE IPO October 2019; editorial estimates for the position in the Polish biotech-oncology sector, as of 2026-05-02.